XOMA's ModulX™ technology enables the modulation of biological pathway(s) using monoclonal antibodies. Implementation of this technology has offered new insights into regulation of signaling pathways, homeostatic control, and disease biology.
With this technology XOMA is generating a new class of drugs with novel mechanisms of action that specifically alter kinetics of interaction between molecular constituents (e.g. receptor-ligand). ModulX™ technology enables expanded target and therapeutic options, and offers a unique approach in the treatment of disease.
ModulX™ technology has been tested and validated:
- Preclinical in vivo and/or in vitro proof of concept has been achieved for several targets
- Multiple product candidates from both the sensitizer and deactivator ModulX™ type classes have been identified